Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2022-02-24 Regulatory Filings
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUÉ DE PRESSE' (Press Release) and provides an update on clinical trial progress, preliminary results, partnership status, and future regulatory discussions for a biopharmaceutical company (Lysogene). It details scientific findings (biomarkers, safety data) and timelines for reporting results (Q3 2022). This format, focusing on key operational and clinical milestones announced via press release, aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K or IR) but rather a summary of operational/clinical progress, and it is not explicitly announcing the *publication* of a formal report (which would suggest RPA), it functions as a high-level operational update. Given the context of clinical trial updates and financial/partnership news, it is most closely related to an Earnings Release (ER) which often includes operational highlights, or a general Regulatory Filing (RNS). Because it is a detailed operational update rather than just a brief announcement of results, ER is a strong candidate, but RNS serves as the best general category for non-standard, material operational updates that aren't strictly earnings summaries. However, in many financial databases, detailed operational updates that are not formal quarterly/annual reports often fall under the 'Earnings Release' umbrella if they contain forward-looking statements and operational milestones, or RNS if they are purely regulatory disclosures. Given the structure and content (clinical updates, partnership status, future guidance), it functions similarly to an Earnings Release summary, but since it's a press release detailing operational progress rather than just financial figures, RNS is the most appropriate catch-all for material, non-standard disclosures. I will classify it as RNS as it is a general regulatory/material announcement that doesn't fit the specific financial report codes.
2022-02-24 French
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces new positive biomarker data for LYS-SAF302 and favorable safety data for LYS-GM101 presented at WORLDSymposium™ 2022. It details clinical trial updates (AAVance and P1-GM-101) and includes forward-looking statements and contact information. This format, announcing key results and updates outside of a formal periodic report (like 10-K or IR), strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing clinical data updates, it functions as an initial release of periodic/material information, fitting the definition of an Earnings Release (ER) which covers periodical financial/operational results highlights. Although it is not strictly 'earnings' in the traditional sense, in the context of biotech/pharma filings, press releases detailing clinical milestones often fall under ER or RNS. Given the detailed nature of the data presented (biomarkers, safety profiles, trial progression), it is more substantial than a simple RNS announcement, making ER the most appropriate fit for a material operational update release. FY 2022
2022-02-11 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces clinical trial updates (biomarker data for LYS-SAF302 and safety data for LYS-GM101) presented at a symposium. This format, focusing on recent operational or clinical achievements rather than comprehensive annual financials (10-K) or detailed quarterly results (IR), strongly suggests an Earnings Release (ER) or a general announcement. Since it is a press release detailing specific, recent operational news (clinical data presentation), it fits best under the Earnings Release category, which often includes operational highlights outside of formal financial statements. It is not a full transcript (CT), a formal annual report (10-K), or a dedicated report publication announcement (RPA) as it contains the substance of the news itself, not just a notice that a report is available. Given the context of reporting recent data/events, ER is the most appropriate fit.
2022-02-11 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and details recent clinical trial updates, management appointments (Dr. Marie Trad), and upcoming presentations at a scientific symposium (WORLDSymposium™ 2022). It provides key operational and clinical highlights rather than comprehensive financial statements (like a 10-K or IR) or a full transcript of a call. This format strongly aligns with an Earnings Release (ER) or a general corporate update. Since it focuses on clinical progress and management changes rather than strictly quarterly financial figures, and it is a press release format, it is best classified as an Earnings Release (ER) as these often bundle operational news with financial highlights, or potentially a Regulatory Filing (RNS) if it were less specific. Given the structure announcing key news points, ER is the most appropriate fit among the specific options, as it serves as the primary communication of recent company status to the market, even if the focus is clinical/operational rather than purely financial results. It is not a short announcement linking to a full report, so RPA/RNS is less likely than ER. FY 2022
2022-02-07 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and provides an update on medical/clinical trial progress, management appointments (CMO), and upcoming presentations at a scientific symposium (WORLDSymposium™ 2022). This format—a brief, timely announcement of key operational and medical milestones, often issued outside of mandatory periodic financial filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific management/governance document, and it serves as an immediate update to the market, it fits best under the general category for timely announcements. Given the content focuses on clinical progress and executive changes rather than just financial results highlights, it is a broad regulatory announcement. However, in many contexts, press releases announcing clinical progress and executive hires are often categorized as Earnings Releases (ER) if they accompany or precede quarterly results, or as Regulatory Filings (RNS) if they are purely informational updates. Since this is a 'Medical Update' press release detailing clinical trial progress and a key executive hire, and it is not explicitly an 'Earnings Release' focusing on financial figures, the most appropriate general category for non-standard, timely corporate news is Regulatory Filings (RNS). It is not short enough to definitively be an RPA, as it contains substantial detail.
2022-02-07 English
Inside Information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and its primary content is reporting the company's cash position as of a specific date (31 December 2021). This format, focusing on key financial highlights for a period (quarter/year-end), aligns perfectly with an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or an Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). Since it provides the initial announcement of key financial metrics (cash position), ER is the most appropriate classification. Q4 2021
2022-01-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.